This presentation systematically addresses the core challenges and efficient execution strategies of supply chain management for MRCTs. It delivers practical management frameworks and partner selection methodologies for clinical operations and supply chain managers to improve trials’ overall execution quality and speed. 本演讲将系统性地阐述多区域临床试验（MRCTs）中供应链管理的核心挑战与高效执行策略。演讲将为临床运营与供应链经理提供实用的管理框架以及合作伙伴选择方法论，以全面提升临床试验的执行质量与速度。
Patient enrollment remains one of the most critical bottlenecks in global drug development, often delaying timelines, increasing costs, and limiting patient access to innovative therapies. Against this backdrop, China has emerged not merely as a region of vast patient numbers, but as a laboratory for systemic innovation in clinical trial execution. 患者入组仍是全球药物开发中最关键的瓶颈之一，常常导致时间线延误、成本上涨，而且还会限制患者获得创新疗法的机会。在这一背景下，中国利用其庞大的患者数量而，不断发展临床试验执行中的体系创新。
- How China Building Beyond “Population Advantage”
- How to Leverage AI and Digital Platforms in Patient Matching
- The Power of Hospital Alliances and Regional Clinical Hubs
- Aligning Patient Recruitment, Clinical Supply Strategy And Site Readiness To Reduce Delays
- How to Adapt China’s Model for International Multi-Center Trials
- 中国不仅是“人口优势”
- 如何利用 AI 与数字平台进行患者匹配
- 医院联盟与区域临床中心的发展
- 患者招募、临床供应策略的动态调整
- 如何将中国模式应用于MRCT
China stands at an inflection point in global biopharma innovation. Having mastered the art of rapid development and commercialization as a fast-follower, the industry is now making a decisive strategic pivot towards becoming a true globald innovator. The rise of China-led international multi-center trials (MRCTs) and landmark global partnerships underscores a new reality: China is no longer just a vast market or a development executor, but a primary source of scientific insight and therapeutic value.
中国正处于全球生物医药创新的关键转折点。随着中国临床的蓬勃发展，现在已经逐渐引领全球创新。由中国主导的多中心临床试验（MRCT）以及具有里程碑意义的全球交易，正在展示着中国在临床试验中的角色转变——从全球申办方的执行中心，转变为科学前沿与医药创新的重要源头
- From “Fast Follower” to Autonomous Innovation
- Leveraging China’s Capabilities for Worldwide Development
- From Local Assurance to Global Collaboration
- Aligning Standards and Achieving Mutual Recognition
- Building an Open, Collaborative Global Network
- 从“快速跟随”到自主创新
- 借助中国能力推动全球开发
- 从本土保障到全球协作
- 标准统一与互认
- 建立开放、协作的全球网络
Clinical development is being reshaped by technology, new regulations, and a patient=centric focus. This panel will analyse key trends, from virtual trials to AI, separating hype from reality and providing a practical roadmap for leading the next generation of clinical research.
临床开发正在受到技术、新法规和以患者为中心理念的重塑。本圆桌将分析从虚拟试验到 AI 的关键趋势，区分炒作与现实，并为引领下一代临床研究提供实用路线图。
- Practical Implementation of DCTs & Hybrid Models
- Integrating RWE, AI, and Advanced Analytics
- Evolving from Recruitment to True Engagement
- Adapting SOPs, Vendor Partnerships, and Risk Management
- Regional Variations in Adopting Next-Generation Trials
- DCT 与混合模式的实践落地
- 整合 RWE、AI 与高级分析
- 从患者招募迈向真正的患者参与
- 调整 SOP、供应商伙伴关系与风险管理
- 下一代试验在不同区域的采用差异
